MTE #15: Ileal Bile Acid Transporter Inhibitors for Cholestatic Liver Disease—Therapeutic Promise for Symptoms and Disease Modification? (Ticketed)

Ileal bile acid transporter (IBAT) inhibitors have emerged as a novel and increasingly relevant therapeutic class in the management of cholestatic liver diseases. Initially developed to address cholestatic pruritus through interruption of enterohepatic bile acid circulation, these agents have demonstrated meaningful symptomatic benefit across multiple cholestatic conditions. However, growing clinical experience and evolving mechanistic insights have raised important questions regarding their potential role beyond symptom control. Presented by the Cholestatic Autoimmune Liver Disease Special Interest Group, experts in this session provide a focused review of IBAT inhibitors, including their mechanism of action, clinical trial data, and current use in cholestatic liver diseases. Presenters highlight the distinction between symptomatic management and the emerging hypothesis that IBAT inhibition may influence disease biology, inflammation, and progression.